Education
About Us
Working with TipRanks
Follow Us
Repligen Corp (RGEN)
NASDAQ:RGEN
Earnings Data
Report Date
Aug 05, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
0.4Last Year’s EPS
0.33Same Quarter Last Year
Moderate Buy
Based on 17 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Apr 29, 2025
|% Change Since: -9.21%
|Next Earnings Date:Aug 05, 2025
Earnings Call Sentiment|Positive
Repligen Corporation had a strong start to 2025 with notable achievements in revenue growth, strategic acquisitions, and product launches. However, there are challenges in specific segments such as capital equipment, China, and small biotech companies. Despite these challenges, the company's strategic initiatives and strong order performance indicate a positive outlook for the year.Company Guidance
In the first quarter of 2025 earnings call, Repligen Corporation provided guidance for the full fiscal year, maintaining its organic growth expectations despite macroeconomic uncertainties. The company anticipates organic revenue growth between 9.5% to 13.5%, with non-COVID organic growth projected at 11.5% to 15.5%. Repligen also raised its reported revenue guidance to a range of $695 million to $720 million, incorporating the recent acquisition of 908 Devices' bioprocessing portfolio. The firm expects adjusted gross margins between 52% to 53%, reflecting a year-over-year expansion. Repligen highlighted its strategic focus, including innovations like the Metanova mixer and progress in its chromatography and analytics franchises, while successfully navigating potential tariff impacts and foreign exchange headwinds. The company remains optimistic about its opportunities across resilient end markets, emphasizing a strong order backlog and a diversified customer base.Strong Organic Revenue Growth
Repligen Corporation reported 11% organic revenue growth for Q1 2025, and 14% growth on an organic non-COVID basis.
Biopharma Revenue Surge
Biopharma revenues reached the highest level ever, excluding COVID, with more than 20% year-over-year growth.
Orders Increase Significantly
Orders were up in the high teens year-over-year, with all franchises growing in double digits.
Strategic Acquisition of 908 Devices' Bioprocessing Portfolio
Repligen acquired 908 Devices' bioprocessing portfolio, aiming to accelerate the digitization of bioprocessing.
Geographical Performance
North America and Europe showed strong growth with 13% increases, while Asia (excluding China) grew by 12%.
Launch of New Products
The company launched the Metanova MixOne, a single-use mixer, and reported positive feedback from the INTERFACE conference.
---
RGEN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
RGEN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Apr 29, 2025 | $143.63 | $139.43 | -2.92% |
| Feb 20, 2025 | $150.73 | $162.67 | +7.92% |
| Nov 12, 2024 | $139.51 | $148.59 | +6.51% |
| Jul 30, 2024 | $138.00 | $160.59 | +16.37% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Repligen Corp (RGEN) report earnings?
Repligen Corp (RGEN) is schdueled to report earning on Aug 05, 2025, TBA Not Confirmed.
What is Repligen Corp (RGEN) earnings time?
Repligen Corp (RGEN) earnings time is at Aug 05, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RGEN EPS forecast?
RGEN EPS forecast for the fiscal quarter 2025 (Q2) is 0.4.
---